Strategic perspective.
Broad operational experience.
Extensive transactional expertise.
Jean-Pierre Naegeli
Jean-Pierre Naegeli, Managing Partner

Mr. Naegeli is a Managing Partner at Oberland Capital. Previously, he was a partner at Paul Capital, a leader in healthcare royalty investing. Prior to joining Paul Capital, Mr. Naegeli spent nearly a decade at Johnson & Johnson, initially in operational and corporate roles, including assessing healthcare technologies across all divisions, followed by five years in principal investing at Johnson & Johnson Development Corporation, the strategic investment and venture capital subsidiary of Johnson & Johnson. In addition, Mr. Naegeli has extensive engineering experience in Europe. He received a Masters in Public and Private Management from the Yale School of Management, and his Diploma in engineering from the Swiss Federal Institute of Technology.

Andrew Rubinstein
Andrew Rubinstein, Managing Partner

Mr. Rubinstein is a Managing Partner at Oberland Capital. Previously, he was a Partner at Paul Capital, a leader in healthcare royalty investing. Prior to joining Paul Capital, he was CEO of Microban International, Ltd. a global licensing business focused on antimicrobial technologies. Mr. Rubinstein had previously worked as an investment banker in the Financial Sponsors Group at Merrill Lynch & Co. He earned a B.A. from the University of Pennsylvania, a J.D. from New York University School of Law, and an M.B.A. from New York University Stern School of Business.

William Clifford
William Clifford, Partner

Mr. Clifford is a Partner at Oberland Capital. Previously, Mr. Clifford was a Principal with Paul Capital where he was responsible for evaluating, structuring, executing, and managing healthcare royalty investments. Prior to joining Paul Capital, Mr. Clifford was an Associate at Health Advances where he led strategy consulting engagements for clients in the biotechnology, pharmaceutical, medical device, and diagnostics sectors. Previously, Mr. Clifford worked at Cap Gemini Ernst & Young's Center for Business Innovation. While attending graduate school, Mr. Clifford worked at In-Q-Tel where he evaluated biotechnology investment opportunities. Mr. Clifford received his M.S. in Biochemistry and Molecular Biology from Georgetown University and his B.A. from Kenyon College.

Michael Bloom
Michael Bloom, Principal

Mr. Bloom is a Principal at Oberland Capital. Previously, Mr. Bloom was an Associate at Paul Capital where he was primarily focused on evaluating and structuring healthcare royalty investments. Prior to joining Paul Capital, Mr. Bloom was a Consultant at the Frankel Group where he worked on due diligence, technology assessment and acquisition analysis for clients in the healthcare industry. Previously, Mr. Bloom worked with Innovative Health Solutions focusing on health economics and outcomes research. Mr. Bloom earned his M.B.A with honors from the Wharton School’s Healthcare Management Program and his B.A. from Colby College.

Jesper Wiklund
Jesper Wiklund, Managing Director Europe

Mr. Wiklund is a Managing Director, Europe at Oberland Capital. Previously, he was the Chief Executive Officer of InDex Pharmaceuticals, a Swedish drug development company focused on the gastrointestinal market with an asset in phase III development. Prior to joining InDex he was responsible for Business Development at Swedish Orphan Biovitrum. Prior to that, Mr. Wiklund worked in the United States for Wyeth Pharmaceuticals and Elan Pharmaceuticals as well as in Germany for Evotec. Over the course of his career, Mr. Wiklund has completed strategic transactions with an aggregate value exceeding $1 billion and he has raised four rounds of Venture Capital from top-tier European Investors. He holds an M.B.A. from Harvard Business School and a Bachelor of Science in Biology from St. Mary’s College of California. Mr. Wiklund is an employee of Wiklund Biotech Consulting.

David Dubinsky
David Dubinsky, Chief Financial Officer

Mr. Dubinsky is the CFO at Oberland Capital. Prior to joining Oberland Capital, Mr. Dubinsky was a Managing Director and CFO at Siguler Guff & Company, a private equity firm with over $10 billion of assets under management. Mr. Dubinsky oversaw the accounting and client reporting functions of the Firm. Previously, Mr. Dubinsky was a Manager within the Assurance & Advisory Business Services department at Ernst & Young. Mr. Dubinsky holds a B.S. in Accounting from Binghamton University, a State University of New York, and is a Certified Public Accountant in the State of New York.

Johnna Schifilliti
Johnna Schifilliti, Office Manager

Ms. Schifilliti is the Office Manager at Oberland Capital. Previously, she was an Associate Director of Marketing in KPMG LLP’s private equity practice. Ms. Schifilliti was responsible for the development and deployment of national private equity marketing programs including budget and strategic planning, credentials and collateral management, thought leadership development and execution, public relations, event planning and project management. Ms. Schifilliti began her career as an associate in KPMG’s audit practice where she spent three years serving higher education and nonprofit clients. Johnna received a B.S. in Accountancy from Villanova University.